<SEC-DOCUMENT>0001022079-18-000131.txt : 20180525
<SEC-HEADER>0001022079-18-000131.hdr.sgml : 20180525
<ACCEPTANCE-DATETIME>20180525165048
ACCESSION NUMBER:		0001022079-18-000131
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180524
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180525
DATE AS OF CHANGE:		20180525

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QUEST DIAGNOSTICS INC
		CENTRAL INDEX KEY:			0001022079
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				161387862
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12215
		FILM NUMBER:		18862187

	BUSINESS ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094
		BUSINESS PHONE:		9735202700

	MAIL ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNING CLINICAL LABORATORIES INC
		DATE OF NAME CHANGE:	19960903
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dgx8-k052418.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sa5f7e8fc6e0a4e7e92f7ae8ffc28bc22"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WASHINGTON, DC  20549</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.24596391263059%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.24596391263059%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Date of Report </font><font style="font-family:inherit;font-size:11pt;">(Date of Earliest Event Reported)</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">: May 24, 2018</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.24596391263059%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Quest Diagnostics Incorporated</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Registrant as Specified in Its Charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.24596391263059%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Delaware</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(State or other jurisdiction of incorporation)</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.15194681861348%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:21%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">001-12215</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">16-1387862</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Commission File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">500 Plaza Drive</font></div><div style="padding-bottom:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Secaucus, NJ</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">07094</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Zip Code)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(973) 520-2700</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Registrant's telephone number, including area code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.24596391263059%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">see</font><font style="font-family:inherit;font-size:11pt;">&#32;General Instruction A.2. below):</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o </font><font style="font-family:inherit;font-size:11pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o </font><font style="font-family:inherit;font-size:11pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o </font><font style="font-family:inherit;font-size:11pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o </font><font style="font-family:inherit;font-size:11pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Emerging growth company  </font><font style="font-family:Wingdings;font-size:11pt;">o</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:11pt;">o</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 8.01.  Other Events</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On May 24, 2018, Quest Diagnostics Incorporated (the &#8220;Company&#8221;) issued a joint press release with UnitedHealthcare announcing that it has established a long-term strategic partnership with UnitedHealthcare, as the two organizations focus on ways to create more personalized care recommendations and a simpler consumer experience for the more than 48 million people enrolled in UnitedHealthcare plans.  Effective January 1, 2019, the Company will be a contracted, participating provider of clinical laboratory testing services, on a nationwide basis, for all UnitedHealthCare plans, excluding existing lab capitation arrangements.  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 9.01.&#160;&#160;&#160;Financial Statements and Exhibits</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(d)</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.24596391263059%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:14%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="dgxex991052418.htm"><font style="font-family:inherit;font-size:11pt;">Press Release of Company dated May 24, 2018.</font></a></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Signature</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">May 25, 2018</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">QUEST DIAGNOSTICS INCORPORATED</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ William J. O&#8217;Shaughnessy, Jr.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">William J. O&#8217;Shaughnessy, Jr.</font></div><div style="line-height:120%;text-align:left;padding-left:336px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Deputy General Counsel and Secretary</font></div><div style="line-height:120%;text-align:left;padding-left:336px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dgxex991052418.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s35b6bb81e58240ab978309974b5cef75"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:528px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img src="dgx.jpg" alt="dgx.jpg" style="height:54px;width:150px;"></div><div style="line-height:120%;text-align:left;"><img src="uhc.jpg" alt="uhc.jpg" style="height:42px;width:216px;"></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UnitedHealthcare Establishes Long-term Strategic Partnership with Quest Diagnostics</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Beginning Jan. 1, 2019, Quest will be participating as a national provider of laboratory services for all UnitedHealthcare plan participants </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Partnership will include broad range of value-based programs, rewarding high quality, easily accessible laboratory services at the best value and real-time data sharing to drive more personalized care support </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">MINNEAPOLIS and SECAUCUS, N.J.,&#160;</font><font style="font-family:inherit;font-size:11pt;">&#32;(May 24, 2018) - UnitedHealthcare  and Quest Diagnostics (NYSE: DGX) have established a long-term strategic partnership as the two organizations focus on ways to create more personalized care recommendations and a simpler consumer experience for the more than 48 million people enrolled in UnitedHealthcare plans. Quest will be in network for all UnitedHealthcare plan participants beginning Jan. 1, 2019</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font><font style="font-family:inherit;font-size:11pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As part of the expanding relationship, UnitedHealthcare and Quest will collaborate on a variety of value-based programs, bringing the same aligned incentives and enhanced patient experience to lab services as exist today in accountable care arrangements between UnitedHealthcare and more than 1,100 hospitals and 110,000 physicians. Working together, UnitedHealthcare and Quest will strategically change the way they are able to support consumers&#8217; health care needs by using real-time data sharing to help better anticipate people&#8217;s care options - and reducing gaps in care - similar to the model UnitedHealthcare already uses to integrate medical and pharmacy data.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Lab data is quickly becoming the personalized roadmap that identifies the path to the next best action for individual patients,&#8221; said Dan Schumacher, President and Chief Operating Officer, UnitedHealthcare. &#8220;With the addition of Quest to our network we will now be able to work together on an even broader scale, and we appreciate that Quest has helped develop a value-based approach to lab services that will focus on improving patient outcomes, better coordinating care with physicians, and meaningfully reducing costs.&#8221; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;We are pleased to expand our relationship with UnitedHealthcare, and excited about the framework of this agreement, which builds on Quest&#8217;s growing relationship with UnitedHealth Group,&#8221; said Steve Rusckowski, Chairman, President and Chief Executive Officer of Quest Diagnostics. &#8220;We believe consumers are best served when they have access to the unmatched convenience, access, quality and value that Quest offers.  We look forward to serving all UnitedHealthcare members in the U.S., beginning in 2019.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The two companies&#8217; long-term collaboration also sets the foundation for the development of more modern benefit designs focused on incenting individuals to use high quality, cost effective in-network labs while setting industry-leading standards for ease of access and the patient experience. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quest, which is an in-network lab for a limited number of UnitedHealthcare plans in some markets today, has 6,000 patient access points and will be in network nationwide for all plan participants beginning January 1, 2019. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">About Quest Diagnostics</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quest Diagnostics empowers people to take action to improve health outcomes. Derived from a robust research and development program and the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in&#160;the&#160;United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. For more information, please visit&#160;</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.QuestDiagnostics.com</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Conference Call Information</font><font style="font-family:inherit;font-size:11pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quest Diagnostics will hold a conference call beginning at 5:00 p.m. Eastern Time today.&#160; The conference call can be accessed in listen-only mode by dialing 888-455-0391, passcode INVESTOR. The company suggests participants dial in approximately 10 minutes before the call.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-434-5245 for domestic callers or 203-369-0999 for international callers. Telephone replays will be available from approximately 7:00 p.m. Eastern Time on May 24, 2018 until midnight Eastern Time on June 7, 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">About UnitedHealthcare</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">UnitedHealthcare is dedicated to helping people live healthier lives and making the health system work better for everyone by simplifying the health care experience, meeting consumer health and wellness needs, and sustaining trusted relationships with care providers. In the United States, UnitedHealthcare offers the full spectrum of health benefit programs for individuals, employers, and Medicare and Medicaid beneficiaries, and contracts directly with more than 1.2 million physicians and care professionals, and 6,500 hospitals and other care facilities nationwide. The company also provides health benefits and delivers care to people through owned and operated health care facilities in South America. UnitedHealthcare is one of the businesses of UnitedHealth Group (NYSE: UNH), a diversified health care company. For more information, visit UnitedHealthcare at&#160;</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.uhc.com</font><font style="font-family:inherit;font-size:11pt;">&#160;or follow @UHC on Twitter.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.0625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:21%;"></td><td style="width:50%;"></td><td style="width:29%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONTACT:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Denny Moynihan</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Daryl Richard</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quest Diagnostics</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">UnitedHealthcare</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(973) 520-2800&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(860) 702-7779</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">Dennis.J.Moynihan@questdiagnostics.com</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">daryl_richard@uhg.com&#160;&#160;&#160;&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">1</sup></font><font style="font-family:inherit;font-size:9pt;">&#32;Excluding existing lab capitation agreements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>dgx.jpg
<TEXT>
begin 644 dgx.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !! *\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z1F"J23
M@#DDUF^)?$FG>$-!O=9U:Z2STZSC,LTS]@.P]23@ #DD@5\.?$?XS>,?VA->
M70M"AN['1)Y/+MM)M6Q+<C^].P//J5SM ZYQFO,QN84L#%<VLGLENS*I44/4
M^G_&G[4?PU\#326]YXCBO;N,X:WTR-KIE/H2@*@^Q-<1I_[=G@/5=0^R66A^
M*[M\XS;Z:DOX[5E+?I5'X5_L4Z%HT$-[XS*ZQ>X!_LZ%BMM%[,1@N?R7V/6O
MHG2]%T?PGI_DZ=8V6D62#[EO$D*#\@!4T)8RLN>I:"[;OYF:]M+5M(YKPC\9
M/#?C)DBMFU#3[A^%@U;39[-C[ R(%8_0FNXK.L?$>DZI,8;/5+*[E')C@N$=
MOR!K1KTHWMJ[F\;VU844459044V21(8VDD94C4%F9C@ #J2:^;O''[=G@CPW
MJTNFZ'8:CXMGB8JTVGJJP''7:S'+?4+CT-8U*U.BKU'8SG4C35Y.Q])T5\_?
M#']M3P-\0M:AT:]BO/"VJS,(XH]3"^5(Y/""0'ACZ,%SVKZ!ITZL*JO!W'"I
M&HKQ=PHHHK4L**** "BBL;QEXLT_P)X7U/Q!JK2+IVGPF>=H4+N%'7 [TFU%
M78F[*[-FBN9^'/Q$T?XI^$[7Q'H33/IMR\B1M<1&-\HY1LJ?<&NFHC)22:V!
M-25T%%%%,9\6?M??$:[\8?$"R\ :49)K73WC:X@AY-Q=N!L3'?:K#CU<^E?0
M/P(^"MG\)_#R/.D<WB&[0&\N1SL[^4A_NC]3SZ8^>_V2?#9^)GQF\8^/]03S
M8+*^FD@+8P;B5WVG'^S'^19:]Z_:8^+S_"7X>O+8.%U[4W-I89&?+;&7EQ_L
M+S]2M?,X>G#VE3,L1TOR^27Z]/\ ASBIM6=:1R_[07[5EE\,;B;P_P"'(8=8
M\4 8E9SFWLL]-^/O/_L C'<CH?BKQEXN\5_$J^:[\2ZW>:JQ)*PR.1#'ST2,
M?*H^@INFZ;)>3/-.[S32L7>20[F=B<EF/<D]ZZBS\/[EX3)KX[,<\G5D[NR[
M'-+GKO78\T707LI5FM]UM,AW))"2C*>Q!'(-?=G[&OQHU;Q]HNI>&_$=T]]J
MVD*DD%Y,<R3V[$CYSW9" -W4AESSDGY?NO#Y5/N?I7MW[%/A^:'Q]XBU$(1!
M%IRP,W^T\H8#\HVKHR/,IU,5"G%Z/_(JC3=.HK'UI?ZU;:;J.FV<[;)-0D>*
M GH75"^WZE58_P# 36A7B'[4'C#_ (0]?AI<(P\]O%UGA<X)CVR))_XZ^/QK
MV^OTJ,^:<H]CT8RO)Q['S=^WAXXO/"?P;BTZRE>!];O%LYW0X)@",[KG_:VJ
MI]B17>?LY_!_1OA3\.=(CM+2$ZQ>6T=Q?W^P>9-(ZAB-W7:N< =,#U)K&_:\
M^$M_\6OA+-;Z1";G6-+G6_MK=?O3A597C7_:*L<#N0!WKAOV??VP/"LG@JPT
M'QOJ/_"/^(-)B6SDEO(V$=PJ#:&W ?*^  RMCD'&>W Y1IXIRJZ76GZG*W&-
M=N?;0W/VT?@_HWB[X6ZKXH2TAM_$&B1?:5O(T"O-""-\;D?>&TDC/0CCJ:XZ
M/XV>)_\ AB*V\46.IRV?B.PFBTYK_"R.X2X6/<=P()*8!)[Y->=?M)?M8:MX
MDM]?\%:/?Z%K'AN^50NJZ;#/',8]P8Q'>VW=P 2H((/&.@[7Q!X;TV/]@/[-
MX:OHM<2 0WM[/:DG;+]H62<$'E=F2,$ X7-<LJL9U:DJ+^R[^O\ 74YY34IS
M=/L_O/I'X%>(-0\5_![PCK&K7+7FI7NGQS7%PRA2[D<G   _ 5XC^RS\<M?\
M11?%'4O&NN27^F>'V6:-I(HU\B)3.7QM49X0=<]*F^ _[4'P]\+? G0;/5M=
MCL]6TBR^S2Z:R,9Y73(41J!\V[C&/7G%>3_LJ^';OXA?#WXZ:19IY5]JEK&L
M,;<8D87!5#^.!6KK\TJ*A*[L[_=U-/:W=/E=W9_D=OX2\0_&_P#:<_M#Q)X;
M\26W@#PM%<-!8P>4'>;'7<=I+8X!;(&<@#@UVG[/7QM\6W'Q"UKX7?$=87\4
M::AEMK^%0HND4*2"  "2K*X8 9&<C(KYV^ OA#X;>)=!NM.\:>.=>\$>)=/N
M)(YK!M4%G 5!ZH&3 8'(9<YR,]Z]K_9^\ _"'_A;E[JOA#QCKGB'7M!@9I9K
M^X$EO)'(AC+"0QC>%SC.<9QU%8T)5)2A)2U>]Y;_ "Z&=*4VXROOOK^ASOA_
MXB?%/]H_QUXHA\+^.].\"V>DW)AM-*>-6GF0,PWG*EF^[\QZ G&*]'\=6'C[
M3_V5_'L7Q$U+3=3UD64PCDTZ+:/*& I<\!F/7A5QG')KSCQEX/\ V>?C#KFJ
M:YH_CR'P=KZSR--<Q3B".20$YE6.7&[)YW1L,]>IK*^&?C3Q1XV_9L^-&BZE
MJDWB:QT6W:'3]3D#,\J;7+#<WS, J*XW9(#X]*<9.+E&3YFT]4[K[N@*33:D
M[MIZWT^XZ/\ 8MT?XG6OA71M5L]6TB[\ 323Q'1[HLEQ#B5@\D;+&?FW G#,
M00<<=1]A5\L_L6_%KPC9?"KP_P"$;C7+>'Q(UY<1)IKY\URTCR*5&.05.<]*
M^IJ]#!\OL8\KOH=>&M[-6=PHHHKN.H\)_8Y\)KX2^&.K6[(5NF\0:@LQ88.8
MYC"/TC'YUX7^VMKDFJ_&+3]+)/D:;IL>%/3?([,Q_((/PK[5T'P_;^'VU(6W
MRQ7MY)>E ,;7< O^;!F_X%7RO^VK\,K\ZYIWCFQMFGL1;K9Z@T:DF$JQ*2,/
M[I#%<]B!GK7SV:4IQR]PATM]QQ5(.-%170\)\/V8;8*].\,^$[K7-T=C9S7D
MBKN*0H6(''./RKS+P[>+\C#FO5_ >J:HNL6K:&EQ+J:,&C%LA=OQ'IZYXK\,
MQ47*M&,DVF^F_P O,UH6L6=2^%WB+RSM\/ZDQQD[;9C_ $KZ,^!7PY/P[\%I
M'<QA-4OW^TW7JI(PL?\ P%?U)KM]!FO[C1[235+>.TU!D!FAC?<JM[&JGC*\
MU:P\*ZK<:%:+?:Q';LUK;NP =\<=>OKCOC'>OV#)\@P^4MXN,I2=M+JS7RWO
MT_ W=KW/D7]I[Q(WQ%_:,\ ^#].<2Q:1J%NLA!X\^25&<?\  8U7\S7VI7Q5
M^R7\.[_Q9\5M3\9ZRDSKH[RKYERI#R7TF0V<]U4L3Z%EK[5KW,LG.O3EB)JW
M.]/3H<U%-\TWU(;R\@T^TGNKJ9+>V@1I99I&"JB*,EB3T  )S7C?B3PG\"_C
M!K*-J'_"-:MK%P0%EMKU8KF8]ANC=6<_G7?_ !9_Y)7XR_[ M[_Z(>KL>@:;
MXB\)VMAJEC;W]G-:QJ\-Q&'4C8/7^=>C./.^5I->9K)<SY;'+:/\$_AEX&TV
M32[7PSI%E!JP-DZW""22ZRI;RM[DLW"DXS_#GM6MX.^#_@WX?K?)X>T"UTN*
M^3R[J&(L8YEYX9"2IX)'3H2*YCP9XBU&ST/0+ W#7<4/B:[T1;JZ_>236T/V
MD1L6/5AY2J6ZG:?4TOBKQ;?1WFM7&D>*[QC8,RK:VOAZ2[LXI$7+132HC,QR
M"&V.I7/0$5FG3BE)17X$+D23L6]%_9K^&7AWQ(FNZ?X/L+?4HW\V)_F:.)P<
MADC+%%(/3 &.U=+X-^&?A;X>S:C-X<T2UTB74'5[MK<$&9@6()R>VYOSKG$\
M::IXWO/#>F:-<KH3:CHT>N7=V8EFDCB?:$BB#?+N+,<LP( 7IELBUI>I>)-'
M\>#0M2U.'5=.;29[Z&[,"17!D66-=LBK\O <X90 =V",KDN/LHN\8_@AQY%K
M&(SQU^S[\/?B1J)U#Q!X7M+S4#C==QEX)7Q_>:,J6_'-=%X+^'OAOX<Z8VG^
M&M&M-&M6.YUMH\&1O5VZL?<DUY]8ZUXW'PJM/'5WK\!NX],35)M'CLX_LLL0
MC#LF_'F!V7)W!@ Q'RD#GII-4UKQEXJU;3=*U0Z!IFC^3'/<16\<MQ<3R1++
MM'F!E5%1X_X226/0+R1=._,HZOTN"Y+\RCJRCXJ_9M^&?C34GU#5O!^GS7LC
M;Y)H0T#2-W+>65W'ZUUNB^%O#O@7PW_9>FZ=8Z/HD8(:WC18X?FX);/!)[D]
M:XB_\8>*M-TGQ!I#8O=9TFXM ^IV-GYCM93'FX%N"<RH%E!09!*;@,'96-XP
MU==?^#?BYK?Q<OB5 (D61K6.&XM&\Q,K(BA><X(#(I]<TN:G%N48ZV\A7A&[
M2U-[2?@1\+? /B:SU^R\-Z9I.KO<".TFWLH$S X6)"VT,1GA1ZUZ?7$Z]>:K
MX6L_#<$NI?VI/=:S#;2W-Q;QJQC<.2 %  (P.0*I:;=>(OB!)J>H:=X@/A_3
M+>\GL;.&"SBF>5H9#&\LID!X,B. J[?E ).3Q<7&'NQC;R5BURQTBCT.J4VN
M:=;3RPS7]K%-" TD;S*&0'&"03QG(_.N \;>(O$&@RZ%#J6IMHNG/;2-?ZWI
M>G&X07(*!4*L'\F-@7;<P/W0-P[Z"_#_ ,-_$#0;*ZULV7BMI45_[2@S''<
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>uhc.jpg
<TEXT>
begin 644 uhc.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !> <\# 2(  A$! Q$!_\0
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M1W_)O?Q-_P"Q8U/_ -)9*\7,9P>.E%0L^;>[.BDG[)-OH?FS_P $U_B9X?\
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MNT<8>WF>)A[JQ!'YBJM>M?M7_#ZY^&7[1'CO19X3%$=4FO+7(P&MYV\V(CU
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M-NHMO\"*$E&<['P?^PW_ ,GZ:?\ ]?6K_P#HBXK[7_X*=?\ )JNJ?]A.R_\
M1E?#'[$/B#3;7]N/1+Z:]A@L[N\U)(9Y&"H[20SB, G RQ90!W)'TK[P_P""
MEFF7&I?LGZ_);QF5;2]L[B7;R53SE4M^!85>/O'-,.WII'\V*EK1E8X[_@DU
M_P F\>(?^QGN/_26UKZ ^.WB;2/$'P#^+L&EZI9:C-I^@:I:WD=I<)*UM,+2
M3,<@4G8XS]TX-?/'_!)F\@/P \3P>:GG1>))G=,\JK6UN%)'H=K<_P"R:I^
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=Y#T&>=J@ GG&>:]4HH[5E4J3J2YYN[*2459'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
